Autor: |
Sahar, M., Wali, Mohammed H., Marwa, A., Bushra, H. |
Předmět: |
|
Zdroj: |
Biochemical & Cellular Archives; Apr2020, Vol. 20 Issue 1, p1921-1925, 5p |
Abstrakt: |
Epidermal growth factor receptor (EGFR), which also known HER-1 or ErbB-1 is the member of prototype of the type I receptor tyrosine kinase (TK) family. EGFR was expressed in Triple negative breast cancers, (TNBC) in which it defined and clinically detected by the lack of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (Her2/cerbB2/ EGFR2) expression. Somatic mutations that caused overexpression of EGFR and consistent activation of EGFR receptor was reported in a number ofmalignancies. The link between genetic polymorphisms in gene of EGFR and the risk of deferent diseases, containing breast cancer is the increasing interest issue. As EGFR mutations is poorly defined. In this study, part of exon 8,18 and 19 of EGFR gene analyzed for the presence of SNPs We, therefore, search for characterize EGFR mutations in triple negative breast cancers. Thirty samples were selectedfrom triple negative breast tumors for EGFR polymorphisms (mutation) analysis. DNA was extracted from these samples and polymerase chain reaction was performed to amplify exon regions 8, 18and 19 of the EGFR gene. Sequencing of the purified product of PCR was performed, followed by sequencing analysis, EGFR mutations were found in exon 8 of EGFR gene of 30 samples. The obtained results concluded that studying and analyzing SNPs in the EGFR gene would give us a well understanding of proliferation of breast cancer status and also would have a benefit in controlling progression and then treatment cancer of breast. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|